Therapy for the seronegative spondyloarthropathies

Rheumatologists have recently become more circumspect and have begun to demand biologic as well as statistical meaning from the data obtained in therapeutic trials. The same may be applied to therapy for the seronegative spondyloarthropathies. In some respects, the spondyloarthropathies present an even greater problem, because the axial skeleton is even more difficult to evaluate. The studies reviewed here represent the current state of the art, and with the exception of those examining the effects of antimicrobial treatment in reactive arthritis occurring after specific infections, are subject to the same uncertainties. Nonetheless, they represent our immediate point of departure.